JonesResearch downgraded Equillium (EQ) to Hold from Buy without a price target after the company announced that Ono Pharmaceutical (OPHLY) declined the option to acquire itolizumab. Equillium now has full commercial rights, “but there are several roadblocks,” the analyst tells investors in a research note. The firm prefers to wait on the sidelines until Equillium resolves the regulatory and trial design issues.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks